Next Article in Journal
In-Vivo Analysis and Model-Based Prediction of Tensides’ Influence on Drug Absorption
Next Article in Special Issue
Cannabinoid Receptor 2 Alters Social Memory and Microglial Activity in an Age-Dependent Manner
Previous Article in Journal
Resveratrol, EGCG and Vitamins Modulate Activated T Lymphocytes
Previous Article in Special Issue
CB1 Cannabinoid Receptor Signaling and Biased Signaling

Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity

Medical Faculty, Institute for Drug Research, Hebrew University, Jerusalem 91120, Israel
Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK
180 Life Sciences, Menlo Park, CA 94025, USA
Lautenberg Center of Immunology and Cancer Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Mauro Maccarrone
Molecules 2021, 26(18), 5601;
Received: 30 July 2021 / Revised: 9 September 2021 / Accepted: 10 September 2021 / Published: 15 September 2021
Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need. View Full-Text
Keywords: cannabinoid; cannabigerol; anti-inflammatory; obesity cannabinoid; cannabigerol; anti-inflammatory; obesity
Show Figures

Figure 1

MDPI and ACS Style

Kogan, N.M.; Lavi, Y.; Topping, L.M.; Williams, R.O.; McCann, F.E.; Yekhtin, Z.; Feldmann, M.; Gallily, R.; Mechoulam, R. Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules 2021, 26, 5601.

AMA Style

Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE, Yekhtin Z, Feldmann M, Gallily R, Mechoulam R. Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules. 2021; 26(18):5601.

Chicago/Turabian Style

Kogan, Natalya M., Yarden Lavi, Louise M. Topping, Richard. O. Williams, Fiona E. McCann, Zhanna Yekhtin, Marc Feldmann, Ruth Gallily, and Raphael Mechoulam. 2021. "Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity" Molecules 26, no. 18: 5601.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop